A severe hypersensitivity reaction, associated with cough, rash and hypotension, was observed in one patient after 7 months of treatment of ovarian cancer with cetrorelix (10 mg/day). The patient recovered completely within 20 minutes. A causal relationship could not be excluded. Uncommonly, cases of hypersensitivity reactions including pseudo-allergic/anaphylactoid reactions have been reported.
Mild to moderate ovarian hyperstimulation syndrome (OHSS) (WHO grade I or II) have been commonly reported which is an intrinsic risk of the stimulation procedure (see Precautions). Inversely, severe OHSS remains uncommon.
Symptoms like abdominal pain, tension, nausea, vomiting, diarrhoea and breathing difficulties may indicate an OHSS. Inform the doctor immediately, if the patient feels such symptoms.
If the patient notices any unwanted effect not mentioned in this monograph or if the patient is unsure about the effect of this medicine, inform the doctor or pharmacist.
The adverse reactions reported are classified according to frequency of occurrence as follows: (See Table 1.)
Click on icon to see table/diagram/image
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. (See Table 2.)
Click on icon to see table/diagram/image
View ADR Monitoring Form